Stock Analiz

Surrozen, Inc. SRZN

Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026

$31.61Market cap $603M
Open the interactive analysis →

Surrozen, Inc. (SRZN) is a healthcare company listed in the US with a market value of about $603M. In the twelve months to September 30, 2026 it had revenue of $11M and net income of -$390M, a net margin of -3706.4%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -56%.

About Surrozen

Surrozen is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $12M in 2022 to $3M in 2025, a decline of about 34.7% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 223% over three years (dilution for shareholders). It spends 845% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S57.2
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-5.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-67.4%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-2615.1%
ROIC (5-yr avg.)-55.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$11M$3M$11M$0$12M$0—
Net income-$390M-$242M-$64M-$43M-$36M-$55M-$33M
Free cash flow-$31M-$30M-$18M-$41M-$45M-$50M-$30M
EPS (diluted)$-46.96$-32.37$-21.67$-21.33$-15.56$-33.16$-30.73
Net margin-3706.4%-6960.8%-596.6%—-288.0%——
ROIC———-87.5%-42.9%-36.6%-45.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $63.50, 101% above the current price; targets range from $54.00 to $80.00; the consensus rating is “Strong buy”; expected EPS is $-18.78 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Surrozen pay a dividend?

Not currently.

Is Surrozen a good stock to buy?

We do not give buy or sell advice. Surrozen scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.